Navigation Links
Glenmark Initiates Phase IIb Human Trials Globally for its Novel Molecule 'Revamilast'
Date:8/10/2011

an volunteers treated with Revamilast suggests a good ex-vivo inhibition of the inflammatory marker TNF-α with maximum inhibition upto 93%. Based on these results and animal model data, it is expected that Revamilast would be beneficial in a variety of inflammatory disorders. Additionally, Revamilast does not appear to be metabolized to carcinogenic metabolites (ADCP N-oxide and ADCP N-oxide epoxide); and plasma samples from a Phase 1 study analyzed for such metabolites of Revamilast, showed no levels were detected in human plasma.

With the completion of several Phase I studies, Glenmark has initiated a global Phase IIb trial for Revamilast in patients with Asthma. Glenmark has already received approval from respective authorities in the UK, Poland, India and Czech Republic to conduct Phase IIb studies. Regulatory submissions have also been completed in Russia. The primary objective of this 12-week, double blind, placebo controlled, dose range finding study is to evaluate the effects of Revamilast at three doses on lung function (FEV1) in nearly 450 patients with chronic persistent Asthma.

Glenmark has also initiated another global Phase IIb trial with Revamilast in patients with Rheumatoid Arthritis. Glenmark has already received approval from the MHRA, UK, India, Poland and the Philippines to conduct Phase IIb studies for Rheumatoid Arthritis. Regulatory submissions have also been completed in Sri Lanka. The objective is to determine the efficacy of three doses of Revamilast compared to placebo in the treatment of more than 400 patients with active Rheumatoid Arthritis who showed an inadequate response to methotrexate.

In parallel to these two clinical studies, Glenmark is also conducting various other clinical and non-clinical studies to ensure timely entry into Phase III trials. Glenmark intends to initiate Phase III trials for at least one indication in the second half of FY 2012-13

PDE4 inhibitors (Impact o
'/>"/>

SOURCE Glenmark Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Glenmark Announces the Discovery of a Novel Chemical Entity GRC 17536, a TRPA1 Receptor Antagonist, a Potential First-in-Class Molecule Globally
2. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
3. SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London
4. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
5. BioMarin Initiates Phase 1 Trial for BMN 673 in Patients With Advanced Hematological Malignancies
6. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
7. GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
8. CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis
9. Metabolex Initiates Phase 2 Trial of Arhalofenate
10. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
11. TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), ... to the pharmaceutical and biotech industry, has announced that ... the position of Director of Science & Technology. , ... experience in drug metabolism and bioanalysis to EZVS in ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... January 22, 2015 The laboratory information ... has witnessed a number of technological advancements due to ... requirements, growing need to integrate healthcare systems, and increasing ... challenges in system integration. Key players in the market ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... with breakthroughs to highlight, royalty, and the possibility record-setting attendance ... 2007 , and perhaps no geographic region is more eager ... story is the news that Quincy Bioscience , a ... treatment of strokes. , ,The highlight of the conference's first ...
... primary burdens facing a patent applicant before the ... requirement that the claimed invention is not obvious under ... defense raised in patent infringement cases. Yet, overcoming obviousness ... lawsuits, was relatively routine. This changed last week when ...
... Kevin Hayden, secretary of the Wisconsin Department ... president and chief administrative officer for Dean Health ... advance the use of health information technology, particularly ... promote health IT adoption. , ,His 23-year career in ...
Cached Biology Technology:BIO 2007: Wisconsin makes its presence felt 2BIO 2007: Wisconsin makes its presence felt 3BIO 2007: Wisconsin makes its presence felt 4High court sends message on patent obviousness 2High court sends message on patent obviousness 3High court sends message on patent obviousness 4DHC 2007: Hayden says technology creates magic moment for healthcare delivery 2DHC 2007: Hayden says technology creates magic moment for healthcare delivery 3DHC 2007: Hayden says technology creates magic moment for healthcare delivery 4
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
(Date:1/22/2015)... 22, 2015 Infinisource has launched its new NXG series ... The G2 sets a higher standard for collecting attendance and ... solution. With plug-and-play installation, touch screen interface and seamless connection ... robust time collection solution for the small to mid-size employer. ...
Breaking Biology News(10 mins):$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2Infinisource's NXG series sets new time clock standard 2
... even though they do not actually touch your skin are ... student Yu Mike Chi,s dissertation. This technology and the ... team the top spot in the UC San Diego Entrepreneur ... and $15K in legal services. Engineers and physicians are ...
... lot of large particles of dust and pollen in the ... directly to greater precipitation in clouds, Colorado State University atmospheric ... of ice crystals necessary to form precipitation in clouds is ... atmosphere, according to a study by Paul DeMott and Anthony ...
... journal Genetics suggests that mutant maize have ... throughout its various organs More than 40 years ... seeing colors this time, in maize, and the ... State University have identified new genes in maize which ...
Cached Biology News:Wireless sensor startup wins UC San Diego $80K Entrepreneur Challenge 2Wireless sensor startup wins UC San Diego $80K Entrepreneur Challenge 3Amount of dust, pollen matters for cloud precipitation, climate change 2Amount of dust, pollen matters for cloud precipitation, climate change 3'Psychedelic' maize may help increase crop and biofuel yields 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
Collected at a certified USDA establishment located within the United States. All final processing is done by Quad Five employees....
... MasterAmp™ Taq DNA Polymerase is a ... aquaticus. Having optimal activity at temperatures ... thermostable enzyme used for PCR and ... purpose. The enzyme has an intrinsic ...
... Adept CE 4100 high pressure dual piston pump ... added flexibility and utra low drift. The ... photodiode array detection and provides superior stability. ... method development and for monitoring to the highest ...
Biology Products: